Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Scholar Rock Holding Corp (SRRK)

Scholar Rock Holding Corp (SRRK)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 272,750
  • Shares Outstanding, K 26,226
  • Annual Sales, $ 0 K
  • Annual Income, $ -49,330 K
  • 60-Month Beta -0.01
  • Price/Sales 33.07
  • Price/Cash Flow N/A
  • Price/Book 2.12

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/19
See More
  • Average Estimate -0.31
  • Number of Estimates 3
  • High Estimate 0.02
  • Low Estimate -0.52
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.03%

Price Performance

See More
Period Period Low Period High Performance
1-Month
9.30 +15.05%
on 08/14/19
13.96 -23.35%
on 07/18/19
-3.00 (-21.90%)
since 07/16/19
3-Month
9.30 +15.05%
on 08/14/19
22.79 -53.05%
on 05/17/19
-11.33 (-51.43%)
since 05/16/19
52-Week
9.30 +15.05%
on 08/14/19
30.00 -64.33%
on 12/12/18
-4.15 (-27.95%)
since 08/16/18

Most Recent Stories

More News
Scholar Rock Reports Second Quarter 2019 Financial Results and Highlights Business Progress

-- Enrollment on track in the TOPAZ Phase 2 clinical trial of SRK-015 in patients with Type 2 and Type 3 Spinal Muscular Atrophy for preliminary PK/PD results by year-end

SRRK : 10.70 (+2.88%)
Scholar Rock to Present at the 2019 Wedbush PacGrow Healthcare Conference

Scholar Rock Holding Corporation (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced...

SRRK : 10.70 (+2.88%)
Scholar Rock Announces Exercise in Full of Underwriters' Option to Purchase Additional Shares of Common Stock in Public Offering

Scholar Rock Holding Corporation (Nasdaq: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced...

SRRK : 10.70 (+2.88%)
Scholar Rock Announces Positive Final Results from Phase 1 Clinical Trial of SRK-015 in Healthy Volunteers

- SRK-015 was well-tolerated in healthy volunteers across all tested doses, supporting evaluation in the ongoing Phase 2 TOPAZ trial in Spinal Muscular Atrophy (SMA)

SRRK : 10.70 (+2.88%)
Scholar Rock to Present at the Jefferies 2019 Global Healthcare Conference

Scholar Rock Holding Corporation (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced...

SRRK : 10.70 (+2.88%)
Scholar Rock Reports First Quarter 2019 Financial Results and Highlights Business Progress

-- Commenced patient enrollment and dosing in TOPAZ, the Phase 2 clinical trial for SRK-015 in Type 2 and Type 3 Spinal Muscular Atrophy (SMA)

SRRK : 10.70 (+2.88%)
Scholar Rock Announces Initiation of Patient Dosing in Phase 2 Trial of SRK-015 in Spinal Muscular Atrophy

-- Dosing of patients has commenced in TOPAZ, the Phase 2 clinical trial of SRK-015 in Type 2 and Type 3 Spinal Muscular Atrophy (SMA)

SRRK : 10.70 (+2.88%)
Scholar Rock Appoints Akshay Vaishnaw, M.D., Ph.D. to Its Board of Directors

Scholar Rock Holding Corporation (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced...

SRRK : 10.70 (+2.88%)
Scholar Rock Announces Appointment of Lisa Amaya Price as Senior Vice President, Human Resources

Scholar Rock Holding Corporation (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced...

SRRK : 10.70 (+2.88%)
Scholar Rock Presents Additional Preclinical Data Demonstrating a Highly Specific Inhibitor of TGFB1 Activation Can Render Resistant Solid Tumors Vulnerable to PD1 Blockade and Drive Tumor Regression with Combination Therapy

-- TGFB1-specific inhibition by SRK-181-mIgG1 was sufficient to render both TGFB1-expressing and TGFB1/TGFB3 co-expressing mouse tumor models sensitive to anti-PD1 immunotherapy, suggesting TGFB1 is the...

SRRK : 10.70 (+2.88%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

See More Share

Trade SRRK with:

Business Summary

Scholar Rock Holding Corporation is a biopharmaceutical company. It focused on the discovery and development of medicines for treatment of serious diseases. The company's product candidate includes SRK-015 and BMP6 which is in pre-clinical stage. Scholar Rock Holding Corporation is based in Cambridge,...

See More

Key Turning Points

2nd Resistance Point 11.53
1st Resistance Point 11.12
Last Price 10.70
1st Support Level 10.02
2nd Support Level 9.33

See More

52-Week High 30.00
Fibonacci 61.8% 22.09
Fibonacci 50% 19.65
Fibonacci 38.2% 17.21
Last Price 10.70
52-Week Low 9.30

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar